Kraig Biocraft Laboratories Expands Spider Silk Manufacturing with Pursuit of Additional Rearing Center
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has announced plans to acquire an additional silkworm rearing center as part of its multi-facility expansion strategy. This expansion follows 18 months of significant production growth under Dr. Nirmal Kumar's expertise, after relocating its operating headquarters to Asia's traditional silk-producing regions.
The company has achieved record production volumes and established a scalable foundation for recombinant spider silk manufacturing. The planned facility expansion aims to create a production network for continuous rearing cycles, enhanced reliability, and increased capacity to meet growing global demand across industries including textiles, apparel, defense, and consumer goods.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader nel settore della tecnologia della seta di ragno, ha annunciato piani per acquisire un ulteriore centro di allevamento di bachi da seta come parte della sua strategia di espansione su più impianti. Questa espansione segue 18 mesi di significativa crescita della produzione sotto l'esperienza del Dr. Nirmal Kumar, dopo aver spostato la sede operativa nelle regioni tradizionalmente produttrici di seta in Asia.
L'azienda ha raggiunto volumi di produzione record e ha creato una base scalabile per la produzione di seta di ragno ricombinante. L'estensione prevista della struttura mira a creare una rete di produzione per cicli di allevamento continui, una maggiore affidabilità e una maggiore capacità per soddisfare la crescente domanda globale in settori tra cui tessile, abbigliamento, difesa e beni di consumo.
Kraig Biocraft Laboratories (OTCQB: KBLB), líder en tecnología de seda de araña, ha anunciado planes para adquirir un centro adicional de cría de gusanos de seda como parte de su estrategia de expansión de múltiples instalaciones. Esta expansión sigue 18 meses de crecimiento significativo de la producción bajo la experiencia del Dr. Nirmal Kumar, tras trasladar su sede operativa a las regiones productoras tradicionales de seda de Asia.
La compañía ha logrado volúmenes de producción récord y ha establecido una base escalable para la fabricación de seda de araña recombinante. La expansión prevista de las instalaciones tiene como objetivo crear una red de producción para ciclos de cría continuos, mayor fiabilidad y mayor capacidad para satisfacer la creciente demanda global en industrias que incluyen textiles, moda, defensa y bienes de consumo.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 실크 기술의 선두주자로, 다중 시설 확장 전략의 일환으로 추가적인 연쇄 양육 센터를 인수할 계획을 발표했습니다. 이 확장은 Dr. Nirmal Kumar의 전문성 아래 18개월의 의미 있는 생산 성장이 이어진 후, 운영 본사를 아시아의 전통적인 실크 생산 지역으로 이전한 후에 이뤄졌습니다.
회사는 기록적인 생산량을 달성했고 재조합 거미줄 실크 제조를 위한 확장 가능한 기반을 확립했습니다. 계획된 설비 확장은 연속 양육 주기를 위한 생산 네트워크를 만들고, 신뢰성을 높이며, 직물, 의류, 방위, 소비재를 포함한 여러 산업의 증가하는 글로벌 수요를 충족하기 위한 용량을 늘리는 것을 목표로 합니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader dans la technologie de la soie d’araignée, a annoncé des plans pour acquérir un centre supplémentaire d’élevage de vers à soie dans le cadre de sa stratégie d’expansion multi-sites. Cette expansion fait suite à 18 mois d’une forte croissance de la production sous l’expertise du Dr Nirmal Kumar, après avoir déplacé son siège opérationnel vers les régions traditionnelles productrices de soie en Asie.
L’entreprise a atteint des volume de production record et a établi une base évolutive pour la fabrication de soie d’araignée recombinante. L’expansion prévue des installations vise à créer un réseau de production pour des cycles d’élevage continus, une fiabilité accrue et une capacité accrue pour répondre à la demande mondiale croissante dans des secteurs tels que les textiles, l’habillement, la défense et les biens de consommation.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein führendes Unternehmen in der Spinnenseiden-Technologie, hat Pläne angekündigt, ein zusätzliches Seidenspinnerzuchtzentrum als Teil ihrer Mehranlagen-Expansionsstrategie zu erwerben. Diese Expansion folgt 18 Monaten signifikanten Produktionswachstums unter der Expertise von Dr. Nirmal Kumar, nachdem der Hauptsitz des Betriebs in die traditionellen Seiden produzierenden Regionen Asiens verlegt wurde.
Das Unternehmen hat rekordverdächtige Produktionsvolumen erreicht und eine skalierbare Grundlage für die Herstellung von rekombinanter Spinnen-Seide geschaffen. Die geplante Erweiterung der Anlage zielt darauf ab, ein Produktionsnetzwerk für kontinuierliche Zuchtzyklen, verbesserte Zuverlässigkeit und eine erhöhte Kapazität zu schaffen, um der wachsenden weltweiten Nachfrage in Branchen wie Textilien, Bekleidung, Verteidigung und Konsumgüter gerecht zu werden.
مختبرات Kraig Biocraft (OTCQB: KBLB)، رائد في تكنولوجيا حرير العنكبوت، أعلنت عن خطط لاستحواذ على مركز تربيه دود القز إضافي كجزء من استراتيجيتها للتوسع متعدد المنشآت. يأتي هذا التوسع بعد ثمانية عشر شهراً من نمو الإنتاج الكبير وتحت خبرة الدكتور نيمال كومار، عقب نقل مقر التشغيل إلى مناطق إنتاج الحرير التقليدية في آسيا.
حققت الشركة أحجام إنتاج قياسية وأرسَت أساساً قابلاً للتطوير لتصنيع حرير العنكبوت المعاد تركيبه. يهدف التوسع المخطط للمراكز إلى إنشاء شبكة إنتاج لدورات تربية مستمرة، وزيادة الاعتماد، وزيادة القدرة لتلبية الطلب العالمي المتزايد عبر صناعات بما في ذلك النسيج والملابس والدفاع والبضائع الاستهلاكية.
Kraig Biocraft Laboratories (OTCQB: KBLB)，蜘蛛丝技术领域的领导者，宣布计划在其多设施扩张策略中再收购一个蚕蛾饲养中心。此次扩张是在 18个月的显著产量增长之后，由 Dr. Nirmal Kumar 的专业指导推动，迁往亚洲传统蚕丝生产地区的运营总部之后。
公司已实现 创纪录的生产量，并为重组蜘蛛丝制造奠定了可扩展的基础。计划中的设施扩张旨在建立一个连续养殖周期的生产网络，提高可靠性并增加产能，以满足日益增长的全球需求，涵盖纺织、服装、国防和消费品等行业。
- Record production volumes achieved in spider silk manufacturing
- Strategic headquarters relocation to Asia's silk-producing regions enhancing operations
- Expansion plans indicate growing market demand for their products
- Development of scalable manufacturing system under expert leadership
- No specific financial details or acquisition costs disclosed
- Acquisition timeline and completion uncertainty
- Operating on OTC markets rather than major exchanges
ANN ARBOR, Mich., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that it is actively pursuing the acquisition of an additional silkworm rearing center as part of its ongoing multi-facility expansion strategy to produce its revolutionary recombinant spider silk.
This planned addition builds on the significant production growth and operational advancements achieved over the last 18 months, under the guidance of Dr. Nirmal Kumar, one of the world's foremost sericulture experts. Kraig Labs relocated its operating headquarters last year to the heart of Asia's traditional silk-producing regions. Since that time, the Company has delivered record production volumes, streamlined processes, and established a scalable foundation for recombinant spider silk manufacturing.
"The progress we've made in expanding our production platform has exceeded expectations," said Kim Thompson, Kraig Labs' Founder and CEO. "Dr. Kumar's leadership has been critical in transforming our sericulture operations into a robust, scalable manufacturing system. As global demand for sustainable super materials continues to accelerate, we are moving forward with the next step in our multi-facility growth strategy - securing additional rearing capacity to bring spider silk to broader markets."
Through this multi-facility approach, Kraig Labs is creating a production network designed for continuous rearing cycles, greater reliability, and significant capacity increases. By adding new rearing infrastructure, the Company is positioning itself to meet rising global interest from industries ranging from textiles and apparel to defense and consumer goods.
Dr. Kumar will work closely with the Company's production teams to guide the buildout and integration of the new facility once the acquisition is finalized. His expertise has been central to achieving consistency and efficiency in Kraig Labs' large-scale recombinant spider silk operations.
"With every expansion, we are moving closer to realizing the full potential of spider silk as a sustainable material solution," Thompson continued. "This additional facility represents another critical step in our long-term vision to supply the world with affordable, high-quality spider silk."
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is Kraig Biocraft Laboratories' latest expansion announcement?
Where is KBLB's operating headquarters located?
Who is leading Kraig Biocraft Laboratories' production development?
What industries are targeted for KBLB's spider silk products?
What has been KBLB's recent production performance?
